潰瘍性大腸炎(UC)に対する白血球除去療法(L-CAP)の白血球除去特性の検討(<特集>血管病変とアフェレシス)

概要

論文の詳細を見る
Leukocyte removal has been developed for the treatment of ulcerative colitis (UC). Changes in blood cell, coagulation and fibrinolysis systems were examined during leukocyteapheresis using Cellsorba^<(R)> for the treatment of six UC patients. Time course changes of leukocyte, leukocytes fraction, platelet count, prothrombin (PT), antithrombin-III (AT-III), and fibrinogen degradation products E fraction (FDP-E) were measured at the inlet and outlet of the leukocyte removal filter during one hour of treatment. Although leukocyte counts were decreased to 38% of the previous levels at 30 min after the start of treatment, they recovered to 80% at the end of treatment. The reduction rate of both leukocytes and platelets was 100% at 15 min after the start of treatment, and it was maintained even at the end of treatment. Granulocytes, monocytes, and lymphocytes also decreased to less than the detection limit on the outlet side of the filter at 15 min and both granulocytes and monocytes were still less than the detection limit at the end of treatment. Changes in PT, AT-III and FDP-E were not observed during treatment. These results suggest that Cellsorba^<(R)> is effective for removing etiologial substances of UC such as leukocytes or platelets without having an adverse effect on coagulation and fibrinolysis systems.
日本アフェレシス学会の論文
2003-05-31